Medication info
Piofine Tablets 15mg (Pioglitazone Hydrochloride)

Piofine Tablets 15mg (Pioglitazone Hydrochloride)

Prescription medicationTabletOral
Ingredient · strength
Pioglitazone Hydrochloride›16.53mg / 1 tablet
Manufacturer / importer
HLB Pharmaceuticals Co., Ltd.
Appearance
White to grayish-white, convex cylindrical tablets
Packaging
30 tablets/bottle, 100 tablets/bottle
Approval status
Active

MFDS item code 200704317 · Approved 2007.04.12 · Insurance code 647301200

Summary

Main use
Improvement of glycemic control in type 2 diabetes mellitus
Who takes it
Adults · Children
Adult dose
This medication is administered orally once daily, regardless of meals. Diabetes management should be individualized for each patient. Ideally, response to treatment should be assessed by monitoring glycated hemoglobin (HbA1c), which is a more accurate diagnostic measure than fasting blood glucose (FBG). Glycated hemoglobin reflects blood glucose levels over the past 2 ~ 3 months. Clinically, this medication should be administered for an adequate period to evaluate changes in glycated hemoglobin (at least 3 months), provided that glycemic control in the patient with diabetes does not worsen. 1. Monotherapy This medication may be initiated as monotherapy at 15 mg of pioglitazone once daily in patients whose blood glucose is not adequately controlled with diet and exercise. If the initial dose does not provide sufficient efficacy, the dose may be increased to up to 30 mg once daily. Combination therapy should be considered in patients who do not respond adequately to monotherapy. 2. Combination therapy 1) Sulfonylureas: This medication may be administered in combination with a sulfonylurea; the initial dose is 15 mg once daily. When used in combination with this medication, the current sulfonylurea may be continued at the same dose and regimen. However, the sulfonylurea dose should be reduced if the patient develops symptoms of hypoglycemia. 2) Metformin: This medication may be administered in combination with metformin; the initial dose is 15 mg once daily. When used in combination with this medication, the current metformin may be continued at the same dose and regimen. It is unlikely that the metformin dose will need to be adjusted because of hypoglycemic symptoms during combination therapy with this medication. 3) Insulin: This medication may be administered in combination with insulin at a dose of 15 mg once daily. The current insulin dose may be continued when combination therapy with this medication is initiated. However, the insulin dose may be reduced by 10 ~ 25 % if a patient receiving this medication in combination with insulin develops symptoms of hypoglycemia or the plasma glucose concentration decreases to 100 mg/dL or less. Subsequent dose adjustments should be made individually according to glycemic control. Maximum recommended dose For monotherapy or combination therapy with a sulfonylurea, metformin, or insulin, doses exceeding 30 mg once daily are not recommended. Dose adjustment is not recommended in patients with renal impairment (see Renal Impairment under General Precautions). Therapy with this medication should not be initiated if the patient has clinical evidence of active liver disease or elevated serum aminotransferase levels (ALT at least 2.5 times the upper limit of normal) at the time treatment is started (see Hepatic Effects under Adverse Reactions and General Precautions). Monitoring of liver enzymes is recommended in all patients before starting therapy and periodically thereafter. There are no data on the use of this medication in combination with other thiazolidinediones.
Child dose
Administration is not recommended in children under 18 years of age because there is no experience with its use in this age group.

Ingredients

Manufacturer
HLB Pharmaceuticals Co., Ltd.

Efficacy & effects

Improvement of glycemic control in type 2 diabetes mellitus

  • Type 2 diabetes
View approved original text

This medication is used as an adjunct to diet and exercise for improving blood sugar control in patients with type 2 diabetes. It can be taken alone or in combination with sulfonylureas, metformin, or insulin if there is no improvement in blood sugar levels after using other oral hypoglycemic agents. Additionally, patients with type 2 diabetes require nutritional counseling, weight loss, and regular exercise, as these efforts are important not only for initial treatment but also for maintaining the efficacy of the medication. This medication effectively enhances blood sugar control.

How to take

Adult dose

This medication is administered orally once daily, regardless of meals. Diabetes management should be individualized for each patient. Ideally, response to treatment should be assessed by monitoring glycated hemoglobin (HbA1c), which is a more accurate diagnostic measure than fasting blood glucose (FBG). Glycated hemoglobin reflects blood glucose levels over the past 2 ~ 3 months. Clinically, this medication should be administered for an adequate period to evaluate changes in glycated hemoglobin (at least 3 months), provided that glycemic control in the patient with diabetes does not worsen. 1. Monotherapy This medication may be initiated as monotherapy at 15 mg of pioglitazone once daily in patients whose blood glucose is not adequately controlled with diet and exercise. If the initial dose does not provide sufficient efficacy, the dose may be increased to up to 30 mg once daily. Combination therapy should be considered in patients who do not respond adequately to monotherapy. 2. Combination therapy 1) Sulfonylureas: This medication may be administered in combination with a sulfonylurea; the initial dose is 15 mg once daily. When used in combination with this medication, the current sulfonylurea may be continued at the same dose and regimen. However, the sulfonylurea dose should be reduced if the patient develops symptoms of hypoglycemia. 2) Metformin: This medication may be administered in combination with metformin; the initial dose is 15 mg once daily. When used in combination with this medication, the current metformin may be continued at the same dose and regimen. It is unlikely that the metformin dose will need to be adjusted because of hypoglycemic symptoms during combination therapy with this medication. 3) Insulin: This medication may be administered in combination with insulin at a dose of 15 mg once daily. The current insulin dose may be continued when combination therapy with this medication is initiated. However, the insulin dose may be reduced by 10 ~ 25 % if a patient receiving this medication in combination with insulin develops symptoms of hypoglycemia or the plasma glucose concentration decreases to 100 mg/dL or less. Subsequent dose adjustments should be made individually according to glycemic control. Maximum recommended dose For monotherapy or combination therapy with a sulfonylurea, metformin, or insulin, doses exceeding 30 mg once daily are not recommended. Dose adjustment is not recommended in patients with renal impairment (see Renal Impairment under General Precautions). Therapy with this medication should not be initiated if the patient has clinical evidence of active liver disease or elevated serum aminotransferase levels (ALT at least 2.5 times the upper limit of normal) at the time treatment is started (see Hepatic Effects under Adverse Reactions and General Precautions). Monitoring of liver enzymes is recommended in all patients before starting therapy and periodically thereafter. There are no data on the use of this medication in combination with other thiazolidinediones.

Child dose

Administration is not recommended in children under 18 years of age because there is no experience with its use in this age group.

Precautions

This medication is used for the treatment of type 2 diabetes and works to improve insulin resistance. This medication may burden the heart in some patients and should not be used in patients with heart failure or a history of heart failure. During treatment, weight gain and edema may occur, and if these symptoms appear, consult a physician. Moreover, this medication should not be administered to patients with a history of bladder cancer or those with active bladder cancer. Patients with impaired liver function or severe renal impairment should use this medication with caution. Women who are pregnant or may become pregnant must consult a physician before taking this medication, and it is advisable for premenopausal women to take appropriate measures to prevent pregnancy. When used in combination with other hypoglycemic agents, the risk of hypoglycemia may increase, so it is essential to carefully monitor the associated medications and symptoms. During treatment, regular blood sugar and liver function tests should be conducted, and any sudden weight gain, shortness of breath, or edema should be reported immediately to healthcare professionals. In case of overdose, there may not be any specific symptoms; however, appropriate treatment must be obtained according to medical advice. This medication should not be used in children or adolescents under 18 years of age, as safety and efficacy have not been established. It should be administered to elderly patients with caution, especially those over 75 years old.

Side effects

Congestive heart failure, excessive and rapid weight change, shortness of breath, edema, fluid retention, swelling, headache, sinusitis, myalgia, pharyngitis, abdominal distension, weight gain, hypoglycemia, urinary tract infection, low back pain, dizziness, diarrhea, elevated serum creatine kinase, hypertension, heart failure, limb pain, chest pain, death due to cardiovascular factors, hospitalization due to exacerbation of congestive heart failure, emergency room visits due to congestive heart failure, cardiovascular adverse events, dizziness, loss of appetite, constipation, upper abdominal pain, chest discomfort, fatigue, weakness, indigestion, nausea, shortness of breath, itching, chest discomfort, tremors, chills, gastrointestinal disorders, abdominal pain, epigastric discomfort, numbness, muscle rigidity, discomfort in the head, increased liver enzymes, exacerbation of liver disease, urticaria, eczema, arthralgia, knee abnormalities, arm weakness, proteinuria, increased serum creatinine, anxiety, insomnia, drowsiness, simple herpes, blurred vision, orthostatic hypotension, palpitations, stroke, sexual dysfunction, myocardial infarction, weight gain, edema, heart failure, macular edema, fractures, liver failure, bladder cancer

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a tightly sealed container to protect it from air and moisture. Additionally, it is best to keep the medication at room temperature between 1 to 30 degrees Celsius, away from extreme heat or cold.

Appearance and packaging

Appearance

White to grayish-white, convex cylindrical tablets

Package unit

30 tablets/bottle, 100 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.